StockData
MoonLake Immunotherapeutics logo

MoonLake Immunotherapeutics (MLTX) stock

MLTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 1/30
$11.25−0.48 (-4.09%)

Close on Nov 17, 2026Market cap $957.45MP/E –Yield –

MoonLake Immunotherapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

MoonLake Immunotherapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$225.18M. For fiscal 2025 it was -$196.01M. The highest annual figure on record is -$611.07K in fiscal 2021.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$196.01M–
FY2024Dec 31, 2024-$116.59M–
FY2023Dec 31, 2023-$42.78M–
FY2022Dec 31, 2022-$55.89M–
FY2021Dec 31, 2021-$611.07K–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$55.56M–
Q1 FY2026Mar 31, 2026-$66.29M–
Q4 FY2025Dec 31, 2025-$58.79M–
Q3 FY2025Sep 30, 2025-$44.54M–
Q2 FY2025Jun 30, 2025-$54.53M–
Q1 FY2025Mar 31, 2025-$38.14M–
Q4 FY2024Dec 31, 2024-$48.47M–
Q3 FY2024Sep 30, 2024-$25.28M–
Q2 FY2024Jun 30, 2024-$27.89M–
Q1 FY2024Mar 31, 2024-$14.95M–
Q4 FY2023Dec 31, 2023-$12.34M–
Q3 FY2023Sep 30, 2023-$9.25M–
Q2 FY2023Jun 30, 2023-$12.16M–
Q1 FY2023Mar 31, 2023-$9.02M–
Q4 FY2022Dec 31, 2022-$11.60M-142.8%
Q3 FY2022Sep 30, 2022-$9.35M–
Q2 FY2022Jun 30, 2022-$20.76M–
Q1 FY2022Mar 31, 2022-$14.19M–
Q4 FY2021Dec 31, 2021$27.11M–
Q3 FY2021Sep 30, 2021-$2.02M–
Q2 FY2021Jun 30, 2021-$25.60M–
Q1 FY2021Mar 31, 2021-$107.80K–

More MoonLake Immunotherapeutics figures

See a number that looks wrong?